Kura Oncology, Inc.

About Kura Oncology, Inc.

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.

Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.

For additional information, please visit Kura’s website at www.kuraoncology.com.

Website	http://www.kuraoncology.com
Employees	51-200 employees View all Kura Oncology, Inc. employees
Industry	Biotechnology
Phone number	(858) 500-8800
Headquarter	12730 High Bluff Dr, Suite 400, San Diego, California 92130, US
Founded	2014
Keywords	Biomarkers, Research And Development, Oncology, Precision Medicine, Targeted Therapeutics, Oncology, Blood Cancers, Solid Tumors, Biomarkers, Solid Tumors, Précision Medicine, Research And Development, Targeted Therapeutics